Akorn's Q4 results were negatively impacted by manufacturing issues, and the company is dedicating 2019 to remediating the issues, JMP Securities analyst Donald Ellis tells investors in a post-earnings research note. The company also experienced increasing competition for multiple products and lower overall prices impacting revenues, the analyst adds. Ellis believes Akorn's new management team is equipped to expedite its manufacturing remediation and re-start new drug submissions and approvals. However, he finds the stock currently fairly valued and maintains a Market Perform rating on the name.